Thursday, March 28, 2024
ADVT 
International

Trump, after nod to loss, embraces his supporters

Darpan News Desk The Canadian Press, 08 Jan, 2021 06:37 PM
  • Trump, after nod to loss, embraces his supporters

Less than 24 hours after acknowledging his election loss, U.S. President Donald Trump is again urging grassroots supporters to keep the faith.

Trump, whose Twitter account was briefly frozen in the aftermath of the riots on Capitol Hill, finally admitted Thursday that he won't be president much longer.

But he's back tweeting this morning, promising his supporters they will continue to have a "giant voice" going forward and saying he won't attend the inauguration of Joe Biden.

The message comes with Trump's presidency, scheduled to end Jan. 20, now in real danger of ending even earlier.

Democrats enraged by Wednesday's riot, which they say Trump incited, are mobilizing to make him the first president in U.S. history to be impeached twice.

Media reports suggest Vice-President Mike Pence won't support their other option: a constitutional rule that allows an unfit commander-in-chief to be removed from office.

Trump vowed Friday that the 75 million "great American patriots" who voted for him in November would continue to be heard.

"They will not be disrespected or treated unfairly in any way, shape or form," he tweeted.

The message appears aimed at those members of his base who have expressed dismay at Trump's pledge to ensure an orderly transfer of power in 12 days.

Online forums popular with Trump supporters suggest some of them are disillusioned by the outcome of Wednesday's riots and are now losing faith in their leader.

MORE International ARTICLES

AstraZeneca resuming US testing of COVID-19 vaccine

AstraZeneca resuming US testing of COVID-19 vaccine
The AstraZenca vaccine, developed with Oxford University, is one of several coronavirus vaccine candidates in final-stage testing around the world.

AstraZeneca resuming US testing of COVID-19 vaccine

FDA approves first COVID-19 drug: antiviral remdesivir

FDA approves first COVID-19 drug: antiviral remdesivir
The drug, which California-based Gilead Sciences Inc. is calling Veklury, cut the time to recovery by five days — from 15 days to 10 on average — in a large study led by the U.S. National Institutes of Health.

FDA approves first COVID-19 drug: antiviral remdesivir

Here we go again: Trump, Biden reprise debate duel

Here we go again: Trump, Biden reprise debate duel
Instead, they're bracing for another show of vintage Trump, one in which he'll seek to be heard even in spite of his muted microphone.

Here we go again: Trump, Biden reprise debate duel

Getting ready for the gong show: Trump v. Biden II

Getting ready for the gong show: Trump v. Biden II
It's the sequel to last month's debate horror show between Donald Trump and Joe Biden, an invective-laced 90 minutes that laid bare the depths to which political discourse can sink in an American election year.

Getting ready for the gong show: Trump v. Biden II

US overdose deaths appear to rise amid coronavirus pandemic

US overdose deaths appear to rise amid coronavirus pandemic
Davidson lost his job. He started staying home alone in his apartment near Georgetown, Kentucky — depressed and yearning for his recovery support group that had stopped gathering in person, said his cousin Melanie Wyatt.

US overdose deaths appear to rise amid coronavirus pandemic

Pfizer: Mid-November earliest it can seek virus vaccine OK

Pfizer: Mid-November earliest it can seek virus vaccine OK
Another leading U.S. contender, Moderna Inc., previously announced the earliest it could seek authorization of its own vaccine would be Nov. 25.

Pfizer: Mid-November earliest it can seek virus vaccine OK